Agency Forms Undergoing Paperwork Reduction Act Review, 76051-76052 [2022-26888]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 237 / Monday, December 12, 2022 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2022–26887 Filed 12–9–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–23–1279]
lotter on DSK11XQN23PROD with NOTICES1
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘WISEWOMAN
National Program Evaluation’’ to the
Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on August 22, 2022 to obtain
comments from the public and affected
agencies. CDC received two comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
VerDate Sep<11>2014
18:08 Dec 09, 2022
Jkt 259001
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
WISEWOMAN National Program
Evaluation (OMB Control No. 0920–
1279, Exp. 12/31/2022)—Extension—
National Center for Chronic Disease
Prevention and Health Promotion
(NCCDPHP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The CDC has supported the
WISEWOMAN (Well-Integrated
Screening and Evaluation for Women
Across the Nation) program since 1995.
The WISEWOMAN program is designed
to serve low-income women ages 40–64
who have elevated risk factors for
cardiovascular disease (CVD) and have
no health insurance, or are
underinsured for medical and
preventive care services. Through the
WISEWOMAN program, women have
access to screening services for selected
CVD risk factors such as elevated blood
cholesterol, hypertension, and abnormal
blood glucose levels; referrals to heathy
behavior support programs; and
referrals to medical care. WISEWOMAN
participants must be co-enrolled in the
CDC-sponsored National Breast and
Cervical Cancer Early Detection Program
(NBCCEDP).
The WISEWOMAN program is
administered through cooperative
agreements with state, territorial, or
tribal health departments. Each
WISEWOMAN recipient submits to CDC
an annual progress report that describes
program objectives and activities, and
semi-annual data reports (known as
minimum data elements, or MDEs) on
the screening, assessment, and healthy
behavior support services offered to
women who participate in the program.
Participant-level MDEs are de-identified
prior to transmission to CDC.
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
76051
In 2018, CDC released the fifth
funding opportunity announcement
(FOA) for the WISEWOMAN program
(DP18–1816), which resulted in fiveyear cooperative agreements with 24
state, territorial, and tribal health
departments, including six new and 18
continuing awardees from the previous
NOFO. Key program elements were
retained (e.g., provision of screening
services, promotion of healthy lifestyle
behaviors, and linkage to healthy
behavior support services and
community based resources), but a
number of changes were incorporated
into the program at that time. The
current FOA reflects increased emphasis
on three strategies to reduce CVD risk
and support hypertension control and
management, including: (1) tracking and
monitoring clinical measures; (2)
implementing team-based care; and (3)
linking community resources and
clinical services to support care
coordination, self-management, and
lifestyle change.
CDC seeks to conduct a multicomponent evaluation to assess the
effectiveness of the program on
individual, organizational, and
community-level outcomes. The indepth assessment is designed to
complement the routine progress and
MDE information already being
collected from WISEWOMAN program
recipients. The data collection focuses
on obtaining qualitative and
quantitative information at the
organizational and community levels
about process and procedures
implemented, and barriers, facilitators,
and other contextual factors that affect
program implementation and
participant outcomes. Data collection
activities include a Program Survey
with all WISEWOMAN awardee
programs, administered in the second
and fourth program years, and a onetime site visit to each recipient spread
across the three-year data collection
effort. During site visits, semi-structured
interviews will be conducted with
WISEWOMAN staff members and staff
at partner organizations, such as clinical
providers and community-based
resource providers, who are positioned
to provide a variety of perspectives on
program implementation.
CDC requests OMB approval for a
one-year extension of this data
collection, and requests approval for an
estimated 84 annual burden hours.
Participation is voluntary and there are
no costs to respondents other than their
time.
Estimated Annualized Burden Hours
E:\FR\FM\12DEN1.SGM
12DEN1
76052
Federal Register / Vol. 87, No. 237 / Monday, December 12, 2022 / Notices
Number of
respondents
Type of respondents
Form name
WISEWOMAN Recipient Administrators ........
Program survey ..............................................
Site Visit Discussion Guide ............................
Innovation Site Visit Discussion Guide ..........
Site Visit Discussion Guide ............................
Innovation Site Visit Discussion Guide ..........
Site Visit Discussion Guide ............................
Innovation Site Visit Discussion Guide ..........
Site Visit Discussion Guide ............................
Innovation Site Visit Discussion Guide ..........
Recipient partners ...........................................
Healthy behavior support staff ........................
Clinical providers .............................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
(RPP) during the period from June 7, 1976,
through November 26, 1978.
[FR Doc. 2022–26888 Filed 12–9–22; 8:45 am]
John J. Howard,
Director, National Institute for Occupational
Safety and Health.
BILLING CODE 4163–18–P
Authority: [42 U.S.C. 7384q].
[FR Doc. 2022–26929 Filed 12–9–22; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Determination Concerning a Petition
To Add a Class of Employees to the
Special Exposure Cohort
Centers for Disease Control and
Prevention
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
[60Day-23–23BJ; Docket No. CDC–2022–
0139]
AGENCY:
ACTION:
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Notice.
lotter on DSK11XQN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
Grady Calhoun, Director, Division of
Compensation Analysis and Support,
National Institute for Occupational
Safety and Health, 1090 Tusculum
Avenue, MS C–45, Cincinnati, OH
45226–1938, Telephone: 877–222–7570.
Information requests can also be
submitted by email to DCAS@CDC.GOV.
SUPPLEMENTARY INFORMATION: On
September 27, 2022, the Secretary of
HHS determined that the following class
of employees does not meet the
statutory criteria for addition to the SEC
as authorized under EEOICPA:
All International Nickel Company (INCO)
security personnel who worked at any
location within the Reduction Pilot Plant
VerDate Sep<11>2014
18:08 Dec 09, 2022
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Department of Health and
Human Services (HHS) gives notice of a
determination concerning a petition to
add a class of employees from the
Reduction Pilot Plant in Huntington,
West Virginia to the Special Exposure
Cohort (SEC) under the Energy
Employees Occupational Illness
Compensation Program Act of 2000
(EEOICPA).
SUMMARY:
Jkt 259001
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled U.S. National
Authority for Containment of Poliovirus
(U.S. NAC) Data Collection Tools. Data
collection will capture information
relating to a poliovirus containment
breach or incident at a U.S. facility and
will assist the U.S. NAC in the initial
stages of the investigation into the
breach, and ensure that facilities have
programs in place that align with global
poliovirus eradication initiative.
DATES: CDC must receive written
comments on or before February 10,
2023.
SUMMARY:
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
16
8
2
16
2
16
2
16
2
Number of
responses per
respondent
1
1
1
1
1
1
1
1
1
Average
burden per
response
(in hours)
1
90/60
45/60
1
45/60
1
45/60
1
45/60
You may submit comments,
identified by Docket No. CDC–2022–
0139 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
ADDRESSES:
E:\FR\FM\12DEN1.SGM
12DEN1
]]>Agencies
[Federal Register Volume 87, Number 237 (Monday, December 12, 2022)]
[Notices]
[Pages 76051-76052]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-26888]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-23-1279]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``WISEWOMAN National Program Evaluation'' to
the Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on August 22, 2022 to obtain
comments from the public and affected agencies. CDC received two
comments related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
WISEWOMAN National Program Evaluation (OMB Control No. 0920-1279,
Exp. 12/31/2022)--Extension--National Center for Chronic Disease
Prevention and Health Promotion (NCCDPHP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The CDC has supported the WISEWOMAN (Well-Integrated Screening and
Evaluation for Women Across the Nation) program since 1995. The
WISEWOMAN program is designed to serve low-income women ages 40-64 who
have elevated risk factors for cardiovascular disease (CVD) and have no
health insurance, or are underinsured for medical and preventive care
services. Through the WISEWOMAN program, women have access to screening
services for selected CVD risk factors such as elevated blood
cholesterol, hypertension, and abnormal blood glucose levels; referrals
to heathy behavior support programs; and referrals to medical care.
WISEWOMAN participants must be co-enrolled in the CDC-sponsored
National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
The WISEWOMAN program is administered through cooperative
agreements with state, territorial, or tribal health departments. Each
WISEWOMAN recipient submits to CDC an annual progress report that
describes program objectives and activities, and semi-annual data
reports (known as minimum data elements, or MDEs) on the screening,
assessment, and healthy behavior support services offered to women who
participate in the program. Participant-level MDEs are de-identified
prior to transmission to CDC.
In 2018, CDC released the fifth funding opportunity announcement
(FOA) for the WISEWOMAN program (DP18-1816), which resulted in five-
year cooperative agreements with 24 state, territorial, and tribal
health departments, including six new and 18 continuing awardees from
the previous NOFO. Key program elements were retained (e.g., provision
of screening services, promotion of healthy lifestyle behaviors, and
linkage to healthy behavior support services and community based
resources), but a number of changes were incorporated into the program
at that time. The current FOA reflects increased emphasis on three
strategies to reduce CVD risk and support hypertension control and
management, including: (1) tracking and monitoring clinical measures;
(2) implementing team-based care; and (3) linking community resources
and clinical services to support care coordination, self-management,
and lifestyle change.
CDC seeks to conduct a multi-component evaluation to assess the
effectiveness of the program on individual, organizational, and
community-level outcomes. The in-depth assessment is designed to
complement the routine progress and MDE information already being
collected from WISEWOMAN program recipients. The data collection
focuses on obtaining qualitative and quantitative information at the
organizational and community levels about process and procedures
implemented, and barriers, facilitators, and other contextual factors
that affect program implementation and participant outcomes. Data
collection activities include a Program Survey with all WISEWOMAN
awardee programs, administered in the second and fourth program years,
and a one-time site visit to each recipient spread across the three-
year data collection effort. During site visits, semi-structured
interviews will be conducted with WISEWOMAN staff members and staff at
partner organizations, such as clinical providers and community-based
resource providers, who are positioned to provide a variety of
perspectives on program implementation.
CDC requests OMB approval for a one-year extension of this data
collection, and requests approval for an estimated 84 annual burden
hours. Participation is voluntary and there are no costs to respondents
other than their time.
Estimated Annualized Burden Hours
[[Page 76052]]
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
WISEWOMAN Recipient Administrators.... Program survey.......... 16 1 1
Site Visit Discussion 8 1 90/60
Guide.
Innovation Site Visit 2 1 45/60
Discussion Guide.
Recipient partners.................... Site Visit Discussion 16 1 1
Guide.
Innovation Site Visit 2 1 45/60
Discussion Guide.
Healthy behavior support staff........ Site Visit Discussion 16 1 1
Guide.
Innovation Site Visit 2 1 45/60
Discussion Guide.
Clinical providers.................... Site Visit Discussion 16 1 1
Guide.
Innovation Site Visit 2 1 45/60
Discussion Guide.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2022-26888 Filed 12-9-22; 8:45 am]
BILLING CODE 4163-18-P
